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PET-positive fibrous dysplasia - a potentially
misleading incidental finding in a patient
with intimal sarcoma of the pulmonary artery
Abstract Benign bone tumors can
show an increased FDG uptake in
FDG-PET/CT investigations. In the
presented case, an incidentally de-
tected PET-positive asymptomatic
fibrous dysplasia was initially
misinterpreted as a metastasis in a
patient with intimal sarcoma of the
pulmonary artery.
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Introduction
Fibrous dysplasia (FD) is a developmental disorder in
which normal bone marrow is replaced with fibro-osseous
tissue. Patients are often asymptomatic, and FD is often
detected incidentally on radiographs, computed tomogra-
phy (CT) or bone scans. FD can lead to complications like
deformity, pathologic fractures and—rarely—malignant
transformation. FD can be monostotic or polyostotic.
Polyostotic FD may be a component of the McCune-
Albright syndrome [1–4]. 18-fluoro-deoxyglucose positron
emission tomography (FDG-PET/(CT) is increasingly used
for the staging of different malignant diseases [5, 6]. FDG
is not a tumor-specific agent, and an increase in FDG
uptake can be shown by many benign or physiologic
“disorders” , such as infections and inflammations [7, 8],
brown fatty tissue [9], traumatic lesions [10], ovaries [11]
and benign tumors like Warthin`s tumor of the parotid
gland [12]. If PET/(CT) is performed to stage malignan-
cies, an FDG uptake in benign lesions can lead to their
misinterpretation as metastases. To our knowledge, there is
no report in the literature of a biopsy-proven PET/CT-
positive fibrous dysplasia.
Case report
A 40-year-old male non-smoker was presented who had
had a cough for 3 months and suffered from weight loss,
night sweat and recurrent haemoptysis. A chest X-ray and a
contrast-enhanced chest CT scan showed a mass at the left
hilus, most likely arising from the left pulmonary artery.
The differential diagnosis of a tumor of the intima of the
pulmonary artery, a bronchial carcinoma, tuberculosis or
other tumor was established. A bronchoscopy was not
conclusive. The patient was referred to us with suspicion of
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a pulmonary artery intimal sarcoma, and 18F-FDG-PET/CT
(combined PET/CT in-line system; Discovery ST, GE
Health Systems, Milwaukee, WI, USA) was performed for
staging. The central lung lesion at the left hilus showed an
increased FDG uptake (SUV max. 4.1) (Fig. 1a–c).
Another asymptomatic FDG-active lesion was found in
the proximal diaphysis of the left femur (SUV max. 2.9;
Fig. 1d). Because of the increased FDG uptake, this lesion
was initially interpreted as suspicious for a metastasis of the
lung tumor.
However, due to the recurrent character of the hemop-
tysis, and due to the absence of effective induction therapy
for intimal sarcomas, a lung resection was performed with a
palliative intention. The patient underwent extended left
pneumonectomy. The histology confirmed the presumed
diagnosis of a high-grade intimal sarcoma of the left
pulmonary artery (Fig. 2).
Fig. 1 MIP image (a) demon-
strating an increased FDG up-
take (SUV max. 4.1) centrally in
the left lung (long arrow) and
in the proximal left femur di-
aphysis (short arrow). Axial
fused PET/CT images show that
the tumor has a close relation-
ship to the left pulmonary artery
(b, c; arrow). On axial images
(d) of the lesion in the femur,
“ground-glass” appearance
(asterisk) of the lesion is visible
with increased FDG-uptake
(SUV max. 2.9)
Fig. 2 Hematoxilin and eosin staining (original magnification
400×) of the centrally located, intraluminal tumor of the pulmonary
artery, in a pneumonectomy specimen showing highly pleomorphic
and mitotically active malignant tumor tissue corresponding to a
high-grade spindle-cell intimal sarcoma
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The bone lesion was further evaluated by means of
conventional X-rays (Fig. 3) and MRI (Fig. 4). The X-ray
demonstrated a homogeneous grayish lesion with a
“ground-glass” pattern in the femur. There were no visible
periosteal reactions or destructions, and no deformity could
be detected. MR images presented a T1-hypointense lesion
in the diaphysis with sharp borders and homogenous
contrast enhancement on fat-suppressed T1-weighted im-
ages. All images were reviewed by an experienced
musculoskeletal radiologist together with a nuclear physi-
cian. Because of the typical pattern, the most likely
diagnosis of incidentally detected FD was established. The
lesion was biopsied under fluoroscopic guidance, and the
histology confirmed the diagnosis of FD (Fig. 5).
Discussion
This case demonstrates that an increased FDG uptake in a
clinically occult fibrous dysplasia can be misleading in the
evaluation of a patient with a malignant primary tumor. The
literature on PET and fibrous dysplasia is very limited.
Aoki et al. evaluated primary benign and malignant bone
tumors, and found an increased FDG uptake (SUV max.
>2.0) in three of six patients with fibrous dysplasia. There
was no statistically significant difference in SUV between
FD (n=6; SUV max. 2.05±0.98) and osteosarcoma (n=6;
SUV max. 3.07±0.96) or chrondrosarcoma (n=7; SUV
max. 2.23±0.74) [13]. With a cut-off SUV max. of 2.0,
only 64% of the 52 cases were classified correctly as
benign or malignant. They found out that histiocytic and
giant cell-containing benign bone lesions in particular can
show a high FDG uptake. In another publication, the
authors described a case of a female patient with breast
cancer, where the bone scan showed multiple focal uptakes
due to polyostotic FD. All of the lesions were PET-negative
[14]. Toba et al. described a case of a patient with FD in the
craniofacial bone without an increased FDG uptake [15]. It
is generally accepted that FD is a developmental failure in
the remodeling of primitive bone to mature lamellar bone.
One explanation for the different degrees of FDG metab-
Fig. 3 X-ray of the bone lesion (arrows) showing a slightly
expansile subtrochanteric lesion in the left femur without periostal
reactions or destruction of the cortex indicating a benign tumor.
Homogeneously increased density of the lesion compared with
surrounding normal bone structure
Fig. 4 Coronal contrast-enhanced, fat-suppressed MR image
showing a homogeneous contrast enhancement of the well-defined
lesion (arrows)
Fig. 5 Elastica and van Gieson staining (original magnification
50×) of the fluoroscopically guided biopsy of the left femur lesion:
bland spindle-cell proliferation with bone trabeculae without
osteoblastic rimming and directly ingrowing collagen bundles
(arrow) characteristic of fibrous dysplasia
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olism of FD may be that the turnover of the remodeling
process may have various velocities in different patients in
different stages of the disease. Fibroblasts are the
predominant proliferating cells in FD lesions, and the
difference in SUVamong FD may be due to the difference
in the amount of proliferating fibroblasts or their metabolic
turnover. Furthermore, a bone reaction may be influenced
by the mechanical stress on the lesion, which may be
higher in weight-bearing bones like the proximal femur
than in the face. Experience with FDG-PET and other
fibrous lesions, such as cortical desmoid, desmoplastic
fibroma, nonossifying fibroma and osteofibrous dysplasia,
is also very limited.
A malignant transformation of FD is rare, with reported
prevalences ranging from 0.4% to 4% [16–18]. The most
common malignant tumors reported are osteosarcoma,
fibrosarcoma and chondrosarcoma. The FDG uptake
correlates with the grade of bone sarcomas, and it is
possible that an increased FDG uptake is a sign of the
transformation of a benign tumor into a malignant one, but
this hypothesis has not been proven yet [19, 20].
Unfortunately, because the differentiation, for example,
between enchondroma and low-grade chondrosarcoma is
sometimes impossible even for the pathologist, one can not
expect FDG-PET or PET/CT studies to provide a solution
to this problem.
Other benign conditions with an increased uptake in the
bone are fractures, which can be misleading in tumor
patients. The amount of the FDG uptake of fractures
depends on the time interval between trauma and PET
imaging. In most cases, the different pattern of uptake and
clinical correlation allows an accurate differentiation of a
fracture from malignant tumors [10, 21, 22].
This case also shows that thorough interpretation of the
CT information from the PET/CT study with the help of an
experienced musculoskeletal radiologist is essential to
making a correct diagnosis. CT is still the best technique
for demonstrating the typical radiographic findings of FD:
the “ground-glass” pattern of the bone, the lesion being
characteristically surrounded by a distinct rim of reactive
bone, the endosteal scalloping. With CT, the extent of the
lesion becomes clearly visible.
There are reports suggesting that FD accumulates other
PET tracers: Tsuyuguchi et al. described two cases of FD of
the skull base with mild accumulation (SUV values were
about 2.0) of 11C-methyl-L-methionine on PET [23]. 11C
Met PET is clinically used for the evaluation of brain
tumors [24]. Tsuyuguchi and his colleagues speculated that
“the mechanism of 11C Met uptake in FD is due to
increased metabolism and active transport of this amino
acid because of the increased density of spindle cells”.
We found no publications on FD and 18F-fluoride-PET.
First studies indicate that 18F-fluoride is more sensitive
than a conventional bone scan for detecting skeletal
metastases in patients with prostate, lung or thyroid cancer
[25]. Because 18F- fluoride-PET is also cost-effective,
some authors expect that “classic” bone scans will be
replaced with 18F- fluoride PET completely in the next few
years [26, 27]. 18F-fluoride is a very potential non-specific
bone tracer. Because 18F-fluoride is a bone agent with an
accumulation mechanism that is similar to methylene
diphosphonate (MDP), one might expect that FD would
show a significant uptake, even higher than in FDG-PET
examinations.
The findings of whole-body intergrated PET/CT imag-
ing can clearly affect therapeutic management. Lardinois
and colleagues found extrapulmonary lesions in 110 out of
250 NSCLC patients with PET/CT. In 72 patients, solitary
lesions were present. 32 (46%) of these lesions were
unrelated to the lung primary. In 26 patients, the extrapul-
monary lesion was caused by a benign tumor or an
inflammatory lesion [12]. An extrathoracic solitary FDG
accumulation in a patient with a lung tumor requires a
histopathologic diagnosis, not only to exclude a false
positive result or to confirm an occult metastasis, but also
to diagnose lesions that are not related to the primary.
In conclusion, PET-CT readers should be aware of FDG-
positive benign bone tumors, and should be familiar with
the typical CT appearance of these lesions.
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